The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Non-cash lease expense | - | - | - | 0 |
| Net income (loss) | 240,979 | -134,570 | -225,902 | -535,861 |
| Depreciation | 1,054 | 2,297 | 5,396 | 12,775 |
| Common stock issued for services | - | 0 | 0 | 2,586 |
| Stock-based compensation | 23,344 | 23,360 | 21,127 | 54,067 |
| Accounts receivable, related party | - | - | - | 0 |
| Accounts receivable-Nonrelated Party | - | - | 245,428 | - |
| Accounts receivable | -49,242 | 32,013 | - | 205,534 |
| Other current assets | -69,346 | -102,368 | -121,905 | -157,985 |
| Right-of-use asset | -16,341 | -16,049 | 187,408 | -277,029 |
| Accounts payable-Nonrelated Party | - | - | 215,723 | - |
| Accounts payable | 118,902 | -309,536 | - | 455,366 |
| Accounts payable-Related Party | - | - | 137,764 | - |
| Accounts payable, related party | 26,500 | 72,000 | - | - |
| Deferred revenue | 608,913 | - | -125,000 | 250,000 |
| Accrued expenses | 98,665 | -29,871 | 99,939 | -105,630 |
| Operating lease liability | -16,341 | -16,049 | 187,408 | -277,029 |
| Net cash provided by operating activities | 1,361,945 | -289,192 | -244,308 | 85,754 |
| Purchase of property and equipment | - | 107 | - | 0 |
| Net cash used in investing activities | - | -107 | - | 0 |
| Proceeds received on exercise of warrants | - | - | 0 | 14,800 |
| Proceeds from sale of common stock and exercise of warrants | - | 14,800 | - | - |
| Repayments on notes payable | 54,360 | 72,513 | 85,071 | 190,035 |
| Net cash used in by financing activities | -54,360 | -72,513 | -85,071 | -175,235 |
| Net change in cash and cash equivalents | 1,307,585 | -361,812 | -329,379 | -89,481 |
| Cash and cash equivalents at beginning of period | 1,614,733 | 1,976,545 | 2,395,405 | - |
| Cash and cash equivalents at end of period | 2,922,318 | 1,614,733 | 1,976,545 | - |
Syra Health Corp (SYRA)
Syra Health Corp (SYRA)